



Pharmaceutical Services, 2 Franklin Street, Belfast BT2 8DQ
Telephone No. 028 95 36 0333

To: All Community Pharmacists

6th August 2025

Dear colleague

Medicine Supply Notification: Estradiol (Progynova® TS) 50micrograms/24hours and 100micrograms/24hours transdermal patches
Tier 2 – medium impact

[Medicines Supply Tool – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice](#)

Summary

- Progynova® TS 50micrograms/24hours and 100micrograms/24hours transdermal patches (**once weekly** estradiol patches) will be discontinued from late December 2025 and February 2026, respectively.
- FemSeven® 50micrograms/24 hours and 100micrograms/24 hours transdermal patches (**once-weekly** estradiol patches) remain available and can support the increase in demand.
- Evorel® 50micrograms and 100micrograms and Estraderm® MX 50micrograms and 100micrograms transdermal patches (**twice-weekly** estradiol patches) remain available and can support the increase in demand.

Pharmaceutical Services, 2 Franklin Street, Belfast BT2 8DQ
Telephone No. 028 95 36 0333

Clinicians should not initiate any new patients on Progynova® TS patches and consider prescribing alternative estradiol patches, taking into account previous patches tried, dosing frequency, and intolerance to any of the patch excipients.

Additionally, patients should be counselled on:

- the change in brand and if applicable, change in frequency of applying the patch;
- potential side-effects such as vaginal 'breakthrough bleeding' and irritation caused by wearing a different patch; and
- seeking medical advice to consider alternative hormone replacement therapy (HRT) products if their symptoms are not controlled or they experience unacceptable side effects following the change in estradiol patch.

Actions Required

Clinical Information

These estradiol patches are licensed as HRT for oestrogen deficiency symptoms in post-menopausal women more than 1-year post menopause, and for the prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.

Progynova® TS and FemSeven® are applied to the skin once weekly and Evorel® and Estraderm® MX twice weekly.

Links to further information

[BNF Estradiol](#)

[BNF Sex Hormones Treatment Summary](#)

[SmPC Progynova® TS patches](#)

[SmPC FemSeven® patches](#)

[SmPC Estraderm MX® patches](#)

[SmPC Evorel® Patches](#)